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CHA2DS2-VASc score predicts 
exercise intolerance in young and 
middle-aged male patients with 
asymptomatic atrial fibrillation
Jeong-Eun Yi1, Young Soo Lee2, Eue-Keun Choi3, Myung-Jin Cha3, Tae-Hoon Kim4, Jin-
Kyu Park  5, Jung-Myung Lee  6, Ki-Woon Kang  7, Jaemin Shim8, Jae-Sun Uhm4, Jun Kim9, 
Changsoo Kim10, Jin-Bae Kim6, Hyung Wook Park11, Boyoung Joung  4 & Junbeom Park1
Exercise intolerance among the clinical symptoms in patients with atrial fibrillation (AF) has usually 
been masked by their adjusted life style. We sought to assess the role of CHA2DS2-VASc score to predict 
exercise intolerance in asymptomatic AF patients, and further examine whether the relationship differs 
by age and gender. Among the 6,275 participants of the prospective Korean registry of the Comparison 
study of Drugs for symptom control and complication prevention of Atrial Fibrillation (CODE-AF), 
1,080 AF patients who underwent exercise treadmill testing were studied. Exercise intolerance was 
defined as a peak exercise capacity of 7 metabolic equivalents (METs) or less, and the patients were 
divided into two groups for the analysis: ≤7 METs (n = 131) and >7 METs (n = 949). Patients with 
exercise intolerance had a significantly higher CHA2DS2-VASc score than those without (3.1 ± 1.3 vs. 
2.0 ± 1.5, p < 0.0001). In the multivariate analysis, a higher CHA2DS2-VASc score (OR 1.54, 95% CI 
1.31–1.81, p < 0.0001), corrected QT interval (OR 1.01, 95% CI 1.00–1.02, p = 0.026), and increased left 
atrial volume index (OR 1.02, 95% CI 1.01–1.03, p = 0.001) were found to be independent predictors of 
exercise intolerance. The impact of the CHA2DS2-VASc score on exercise intolerance was significant only 
in male patients aged <65 years (OR 3.30, 95% CI 1.76–6.19, p < 0.0001). The CHA2DS2-VASc score may 
be a feasible risk assessment tool to predict exercise intolerance, especially in young and middle-aged 
male patients with asymptomatic AF.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence of 1–2% in the 
general population1,2. Many patients with AF experience various degrees of impaired exercise tolerance, which 
is associated with an increased morbidity and mortality, and poor quality of life3–5. However, some patients with 
AF are asymptomatic6 and their adjusted life style may also mask the exercise intolerance. Since asymptomatic 
AF patients are more likely to miss out on the appropriate treatment options, their prognosis is worse than that 
of symptomatic patients7–9. Therefore, early detection and treatment of exercise intolerance in these patients 
have important clinical implications. Exercise Treadmill testing (TMT) may be a useful tool to estimate exercise 
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capacity in AF patients, however; it cannot be routinely performed in patients with mental or physical impair-
ment, or conversely, in apparently healthy subjects without symptom10.
The CHA2DS2-VASc score (Congestive HF, hypertension, age ≥75 years [doubled], type 2 diabetes, previous 
stroke or transient ischemic attack (TIA) [doubled], vascular disease, age 65 to 74 years, and sex category) has 
been originally recommended for the stroke risk stratification in AF1. Recently, its usefulness as a risk assessment 
tool for adverse clinical outcomes other than thromboembolic events has also been explored beyond the AF 
field11–13. The aim of our study was to investigate the association between CHA2DS2-VASc score and exercise 
capacity in AF patients. In this study, we tested the hypothesis that the CHA2DS2-VASc score could predict exer-
cise intolerance in asymptomatic AF patients. And we further examined whether the relationship differs by age 
and gender, because age and gender were very important risk factors which influence on exercise intolerance.
Methods
Study population. The COmparison study of Drugs for symptom control and complication prEvention of 
AF (CODE-AF) is a prospective, multicenter, ongoing observational study conducted in patients aged >18 years 
with AF at 10 tertiary hospitals in South Korea. The primary aim of the CODE-AF registry is to compare the out-
comes according to the different medical treatment strategies such as anticoagulation, rate control, and rhythm 
control. The secondary aim of the study is to describe the clinical epidemiology of AF and to evaluate the diagnos-
tic and therapeutic processes applied to patients with AF and their clinical outcomes. The registry was funded and 
designed by the Korea Ministry of Health & Welfare (HI15C1200), which provided national coordinators. And it 
was coordinated by the Korea Heart Rhythm Society, which provides support to related committees and partici-
pating centers. Data are entered into a common electronic database that limits inconsistencies and errors and pro-
vides online help for key variables. Each center has access not only to its own data, but also to data from all other 
participating centers. AF-related symptoms included palpitations, tachycardia, syncope or presyncope, dyspnea, 
orthopnea, shortness of breath on exertion, chest pain, fatigue, or malaise, which were assessed by a self-reported 
questionnaire and classified into three grades based on the EHRA symptom scale. The details of the study design 
has been reported previously14. This study was based on the first released database for enrolled patients between 
June 2016 and April 2017, who were >18 years with non-valvular AF, attended an outpatient clinic, and were 
hospitalized on the same day for AF. All patients were scheduled for clinically follow-up every 6 months, either 
through personal interview or telephone contact. This study was conducted in accordance with the Declaration 
of Helsinki and the relevant guidelines and regulations. The study protocol was approved by the research Ethics 
Committee of Ewha Womans University Mokdong Hospital (No. 216-02-056), and all patients gave their written 
informed consent prior to enrollment. This study was registered in the ClinicalTrials.gov (NCT02786095).
Among the 6,275 participants of the CODE-AF, 1,872 asymptomatic AF patients who underwent exercise 
TMT as a screening exam were selected. From those, 792 patients were excluded for the following reasons: a 
history of congestive HF or myocardial infarction (n = 190), structural or valvular heart disease (n = 142), or radi-
ofrequency catheter ablation of AF (n = 417); presence of an intracardiac device such as a pacemaker or implant-
able cardioverter defibrillator (n = 89); left ventricular (LV) systolic dysfunction (ejection fraction [EF] <50%) 
(n = 105); the presence of stenosis (>50%) on coronary computed tomography (CT) or coronary angiography 
(n = 121); or missing data (n = 77). Finally, a total of 1,080 consecutive patients were eligible for our analysis. The 
CHA2DS2-VASc score was calculated for each patient based on their demographic and clinical information at the 
time of enrollment, and categorized into three groups (0–1 points, 2–3 points, and ≥4 points).
Exercise protocol. All patients underwent maximal, symptom-limited exercise TMT with electrographic 
monitoring using the Bruce or Naughton protocol. ST-segment depression was defined as a ≥1 mm horizontal or 
down-sloping at 80msec from the J point for 3 consecutive beats10. The exercise capacity was measured in peak 
metabolic equivalents (METs) estimated from the basis of the exercise speed and grade using the standardized 
equations. Exercise intolerance was defined as a peak exercise capacity of ≤7 METs15.
Statistical analysis. The continuous variables are presented as the mean ± SD, whereas categorical variables 
are presented as counts and percentages. Comparisons of the variables across the groups were performed using a 
Student t test or a one-way ANOVA combined with a Bonferroni post hoc analysis for continuous variables and 
Chi-square (χ2) or Fisher’s exact test for categorical variables, as appropriate. A multiple logistic regression anal-
ysis was performed to determine the independent predictors of exercise intolerance using covariates identified 
as significant in the univariate analysis or previously known to be important variables. A receiver operating char-
acteristic (ROC) curve was constructed to assess the predictive ability of the CHA2DS2-VASc score for exercise 
intolerance. All statistical analyses were performed using the SPSS version 21.0 software package (IBM SPSS, New 
York, USA). A P < 0.05 was considered to be statistically significant.
Results
Patient demographic characteristics. The 1,080 patients had a mean age of 65 ± 11 years and consisted 
of 769 (71.2%) men. The mean CHA2DS2-VASc score was 2.1 ± 1.5, demonstrating a low CHA2DS2-VASc score 
(0–1) in 407 (37.7%) patients, intermediate score (2–3) in 492 (45.6%), and high score (≥4) in 181 (16.8%). The 
mean peak exercise capacity was 10.5 ± 2.7 METs, and the patients were divided into two groups according to the 
exercise capacity: ≤7 METs (n = 131) and >7 METs (n = 949).
The baseline characteristics are presented in Table 1. The patients with exercise intolerance were older, and 
had a higher prevalence of chronic kidney disease and higher body mass index (BMI). The prevalence of the 
components constituting the CHA2DS2-VASc score, including hypertension, diabetes mellitus, an age ≥75, an 
age 65–74, and a female gender were higher in the patients with exercise intolerance. However, there were no sig-
nificant differences in the proportion of subjects with a stroke or TIA, peripheral artery disease, dyslipidemia, or 
www.nature.com/scientificreports/
3SCIENtIfIC REPoRTS |         (2018) 8:18039  | DOI:10.1038/s41598-018-36185-7
smoking between the two groups. Persistent AF was more frequently found in patients with exercise intolerance, 
but the duration of AF was similar between the two groups. Angiotensin converting enzyme inhibitors (ACEis) 
or angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) were more commonly used in 
patients with exercise intolerance, whereas the use of beta-blockers, digoxin, and antiarrhythmic drugs were 
similar between the two groups.
Difference in the clinical characteristics of the patients with and without exercise intoler-
ance. Patients with exercise intolerance had a significantly higher CHA2DS2-VASc score (3.1 ± 1.3 vs. 
2.0 ± 1.5, P < 0.0001) and larger proportion of intermediate or high-risk categories (Table 2). The peak exercise 
capacity according to the CHA2DS2-VASc score is shown in Fig. 1. As the CHA2DS2-VASc scores increased from 
0 to 7, the peak exercise capacity significantly decreased from 12.1 to 6.5 METs (P < 0.0001) (Fig. 1A), and the 
categorical analysis also showed a significant difference among each risk group according to the CHA2DS2-VASc 
score (P < 0.0001) (Fig. 1B).
Patients with exercise intolerance had a significantly increased QTc interval and had higher E/E’ and left atrial 
volume index (LAVI) than those achieving a peak of more than 7 METs. The resting diastolic blood pressure 
(DBP) and peak exercise heart rate (HR) were significantly lower in the patients with exercise intolerance than 
in those without, as was the proportion of patients achieving ≥85% of their maximum age-predicted heart rate 
(MAPHR). There were no significant differences in the prevalence of exercise-induced ST-segment depression 
between the groups.
Predictors of exercise intolerance in the asymptomatic AF patients. Logistic regression analy-
ses for the association of the clinical variables to exercise intolerance are presented in Table 3. In the univari-
ate analyses, the CHA2DS2-VASc score, BMI, chronic kidney disease, persistent AF, QTc interval, E/E’, LAVI, 
and resting DBP were related to exercise intolerance. After an adjustment for the significant covariates, a high 
CHA2DS2-VASc score (adjusted odds ratio [OR] 1.54, 95% confidence interval [CI] 1.31–1.81, P < 0.0001), pro-
longed QTc interval (adjusted OR 1.01, 95% CI 1.00–1.02, P = 0.026), and enlarged LAVI (adjusted OR 1.02, 95% 
CI 1.01–1.03, P = 0.001) remained as independent determinants of exercise intolerance.
Patients with a CHA2DS2-VASc score of 2–3 (16.5%) and CHA2DS2-VASc score of ≥4 (23.2%) were more 
likely to experience an impaired exercise capacity compared to those with a CHA2DS2-VASc score of 0–1 (2.0%) 
(P < 0.0001) (Fig. 2). Further, the association between CHA2DS2-VASc risk stratification and exercise intolerance 
was significant even after adjusting for the other confounding factors (Supplementary Table 1). In detail, the 
predictive value of the individual components of the CHA2DS2-VASc score were assessed, and we found that 
Variables Total (n = 1,080)
≤7 METs 
(n = 131)
>7 METs 
(n = 949) P value*
Age (years) 65 ± 11 71 ± 8 64 ± 11 <0.0001
  Age <65 509 (47.1) 23 (17.6) 486 (51.2) <0.0001
  Age 65–74 391 (36.2) 64 (48.9) 327 (34.5) 0.001
  Age ≥75 180 (16.7) 44 (33.6) 136 (14.3) <0.0001
Male 769 (71.2) 70 (53.4) 699 (73.7) <0.0001
Body mass index (kg/m2) 24.9 ± 3.2 25.5 ± 3.7 24.8 ± 3.1 0.048
Duration of AF ( ≥ 3 months) 932 (86.3) 114 (87.0) 818 (86.2) 0.893
Type of AF
  Paroxysmal 817 (75.6) 89 (67.9) 728 (76.7) 0.028
  Persistent 234 (21.7) 40 (30.5) 194 (20.4) 0.009
  Permanent 29 (2.7) 2 (1.5) 27 (2.8) 0.566
Diabetes mellitus 263 (24.4) 48 (36.6) 215 (22.7) <0.0001
Hypertension 747 (69.4) 114 (87.0) 633 (66.9) <0.0001
Stroke/TIA 111 (10.3) 97 (10.2) 14 (10.7) 0.892
Peripheral artery disease 22 (22.0) 5 (3.8) 17 (1.8) 0.174
Dyslipidemia 437 (40.7) 54 (41.5) 383 (40.5) 0.826
Chronic kidney disease 100 (9.3) 20 (15.3) 80 (8.4) 0.011
Smoking 405 (37.5) 41 (31.3) 364 (38.4) 0.118
Medications
  ACEi or ARB 381 (35.3) 65 (49.6) 316 (33.3) <0.0001
  Beta-blocker 529 (49.0) 72 (55.0) 457 (48.2) 0.144
  Calcium channel blocker 339 (31.4) 59 (45.0) 280 (29.5) <0.0001
  Digoxin 35 (3.2) 7 (5.3) 28 (3.0) 0.181
  Antiarrhythmic drug 624 (57.8) 70 (53.4) 554 (58.4) 0.283
Table 1. Demographic characteristics. *P value: ≤7 METs vs. >7 METs. Values are presented as the mean ± SD 
or n (%). Abbreviations: MET = metabolic equivalent; TIA = transient ischemic attack; AF = atrial fibrillation; 
ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker.
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hypertension, diabetes mellitus, an age ≥75, an age 65 to 74, and a female gender were associated with exercise 
intolerance (Table 4).
Detection of exercise intolerance in young male AF patients. Finally, we performed subgroup anal-
yses to evaluate whether there were age or gender-specific differences between the CHA2DS2-VASc score and 
exercise intolerance (Table 5). Interestingly, a significant association between the CHA2DS2-VASc score and exer-
cise intolerance was found just in male patients aged <65 years (adjusted OR 3.15, 95% CI 1.84–5.38, P < 0.0001), 
whereas it was not in male patients aged ≥65 years and female patients. In the ROC analysis conducted among 
the male patients aged <65 years, a CHA2DS2-VASc score of ≥2 was identified as the optimal cut-off value for 
predicting exercise intolerance (AUC 0.805, 95% CI 0.68–0.93, P < 0.0001) with a sensitivity of 76.9% and spec-
ificity of 80.3% (Fig. 3).
Variables Total (n = 1,080)
≤7 METs 
(n = 131)
>7 METs 
(n = 949) P value*
CHA2DS2-VASc score 2.1 ± 1.5 3.1 ± 1.3 2.0 ± 1.5 <0.0001
  Low (0–1) 407 (37.7) 8 (6.1) 399 (42.0) <0.0001
  Intermediate (2–3) 492 (45.6) 81 (61.8) 411 (43.3) <0.0001
  High (≥4) 181 (16.8) 42 (32.1) 139 (14.6) <0.0001
Electrocardiography
  QRS duration (ms) 99 ± 19 97 ± 18 100 ± 19 0.147
  QTc interval (ms) 435 ± 32 443 ± 30 434 ± 32 0.001
Echocardiography
  LVEF (%) 64.3 ± 6.2 64.5 ± 6.1 64.3 ± 6.2 0.687
  E/E’ 10.5 ± 4.1 12.3 ± 4.4 10.3 ± 4.0 <0.0001
  LAVI (ml/m2) 39.5 ± 19.4 50.1 ± 28.7 38.0 ± 17.2 <0.0001
Exercise treadmill test
  Resting SBP (mmHg) 122 ± 14 124 ± 14 122 ± 14 0.079
  Resting DBP (mmHg) 76 ± 11 73 ± 12 76 ± 11 0.003
  Resting HR (bpm) 73 ± 15 74 ± 16 73 ± 14 0.206
  Peak exercise HR (bpm) 162 ± 35 137 ± 33 166 ± 34 <0.0001
  Achieved ≥85% of MAPHR 875 (81.0) 76 (58.0) 799 (84.2) <0.0001
  Peak exercise capacity (MET) 10.5 ± 2.7 5.7 ± 1.3 11.2 ± 2.0 <0.0001
  Inducible ST depression 134 (12.4) 20 (15.3) 114 (12.0) 0.290
Table 2. Electrocardiography, Echocardiography, and Exercise treadmill test variables. *P value: ≤7 METs 
vs. >7 METs. Values are presented as the mean ± SD or n (%). Abbreviations: MET = metabolic equivalent; 
LVEF = left ventricular ejection fraction; LAVI = left atrial volume index; SBP = systolic blood pressure; 
DBP = diastolic blood pressure; HR = heart rate; MAPHR = maximum age predicted heart rate.
Figure 1. (A) Changes in the peak exercise capacity according to the CHA2DS2-VASc scores (n = 1,080). (B) 
Categorical analysis for changes in peak exercise capacity among each risk group according to the CHA2DS2-
VASc scores (low vs. intermediate risk group, p < 0.0001; intermediate vs. high risk group, p < 0.0001; low vs. 
high risk group, p < 0.0001).
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Discussion
Although a reduced exercise capacity is commonly found in AF patients, the exact mechanisms remain uncertain. 
Recently, Haskiah F et al. documented the association between the CHA2DS2-VASc score and improvement in 
the functional capacity, however, their study population consisted of acute coronary syndrome patients referred 
for cardiac rehabilitation16. Approximately one third of patients with AF have no obvious AF-related symptoms 
Variables
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
CHA2DS2-VASc score* 1.60 1.41–1.80 <0.0001 1.54 1.31–1.81 <0.0001
BMI (kg/m2) 1.06 1.01–1.12 0.025 1.05 0.99–1.12 0.115
Smoking 0.73 0.50–1.08 0.119 1.34 0.83–2.16 0.229
Chronic kidney disease 1.96 1.15–3.32 0.013 0.97 0.50–1.89 0.924
Persistent AF** 1.69 1.13–2.53 0.011 1.25 0.74–2.13 0.407
Permanent AF** 0.61 0.14–2.59 0.499 0.79 0.09–6.76 0.832
QTc interval (ms) 1.01 1.00–1.02 0.001 1.01 1.00–1.02 0.026
LVEF (%) 1.01 0.98–1.04 0.542 1.01 0.97–1.05 0.659
E/E’ 1.10 1.05–1.15 <0.0001 1.01 0.96–1.07 0.656
LAVI (ml/m2) 1.02 1.02–1.03 <0.0001 1.02 1.01–1.03 0.001
Resting DBP (mmHg) 0.97 0.96–0.99 0.003 0.98 0.96–1.00 0.054
Resting HR (bpm) 1.01 0.99–1.02 0.206 1.01 0.99–1.02 0.259
Use of beta-blocker 1.31 0.91–1.90 0.145 1.14 0.73–1.78 0.572
Table 3. Univariate and multivariate analysis for exercise intolerance. *Excluding congestive heart failure 
component, **versus paroxysmal AF. Abbreviations: OR = odds ratio; CI = confidence interval; BMI = body 
mass index; AF = atrial fibrillation; LVEF = left ventricular ejection fraction; LAVI = left atrial volume index; 
DBP = diastolic blood pressure; HR = heart rate.
Figure 2. Prevalence of exercise intolerance in patients with low, intermediate, and high risk categories of 
CHA2DS2-VASc scores.
Variables
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Congestive heart failure N/A
Hypertension 3.16 1.89–5.30 <0.0001 2.28 1.31–3.96 0.004
Diabetes mellitus 1.97 1.34–2.90 0.001 1.61 1.07–2.42 0.024
Age ≥75 years* 6.84 3.99–11.7 <0.0001 5.03 2.87–8.81 <0.0001
Age 65–74 years* 4.14 2.52–6.80 <0.0001 3.34 2.01–5.56 <0.0001
Stroke/TIA 1.06 0.59–1.92 0.843 0.69 0.37–1.29 0.242
Peripheral artery disease 2.18 0.79–6.00 0.133 2.40 0.82–7.01 0.110
Female 2.44 1.68–3.54 <0.0001 2.13 1.44–3.15 <0.0001
Table 4. Predictive value of the individual components in the CHA2DS2-VASc score. *Versus age <65 years. 
Abbreviations: OR = odds ratio; CI = confidence interval; N/A = not applicable; TIA = transient ischemic 
attack.
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and no noticeable deterioration in quality of life6. Exercise intolerance in these patients is often diagnosed later 
and, thus, results in worse outcomes compared with symptomatic patients7–9. We examined for the first time the 
clinical application of the CHA2DS2-VASc score for assessing the exercise capacity in asymptomatic AF patients. 
Further, our results showed that a high CHA2DS2-VASc score may predict exercise intolerance, especially in 
young and middle-aged male patients (<65 years).
Exercise intolerance in patients with normal LV systolic function is associated with diastolic heart failure 
(DHF), also described as HF with preserved EF (HFpEF)17. Epidemiological studies have documented that AF 
itself causes the LA and LV remodeling, which, in turn, contributes to diastolic dysfunction and HFpEF18–21. 
However, HFpEF is a challenging diagnosis since it requires typical symptoms or signs of HF and evidence of 
diastolic dysfunction, but a normal LV systolic function22. Exercise hemodynamics, especially in stable outpa-
tients with normal EF is largely determined by LV diastolic filling during exercise. For this reason, exercise testing 
has been used not only to identify masked HFpEF, but also to predict the prognosis in patients with HFpEF23,24. 
Our results have important implications in that the CHA2DS2-VASc score may be used as a feasible risk assess-
ment tool for the early detection of HFpEF in apparently asymptomatic AF patients. However, in our study, 
patients with exercise intolerance were more likely to be older and females. Moreover, among the CHA2DS2-VASc 
components, age and female were powerful determinants of exercise intolerance. Although old age and female 
gender are also risk factors for HFpEF22, the possibility of age- or sex-related declines in functional capacity 
cannot be excluded25. Actually, we found that a high CHA2DS2-VASc score was independently associated with 
exercise intolerance only in male patients younger than 65 years. Considering that CHA2DS2-VASc score among 
them is determined only by cardiovascular risk factors except for the age and gender, this finding may further 
support the clinical role of CHA2DS2-VASc score in predicting HFpEF.
Adjusted OR 95% CI P value
<65 years*
Overall (n = 509) 3.15 1.84–5.38 <0.0001
  Male (n = 403) 3.30 1.76–6.19 <0.0001
  Female (n = 106) 2.28 0.78–6.70 0.134
≥65 years**
Overall (n = 571) 1.17 0.98–1.41 0.091
  Male (n = 366) 1.05 0.79–1.41 0.730
  Female (n = 205) 1.19 0.88–1.63 0.265
Table 5. Subgroup analyses stratified by age and gender. *Adjusted for the BMI, smoking, AF type, LVEF, 
E/E’, LAVI, resting HR, and the use of beta-blockers; **Adjusted for the BMI, smoking, AF type, QTc interval, 
LVEF, E/E’, LAVI, resting DBP, resting HR, and the use of beta-blockers. Abbreviations: OR = odds ratio; 
CI = confidence interval; BMI = body mass index; AF = atrial fibrillation, QTc = corrected QT; LVEF = left 
ventricular ejection fraction; LAVI = left atrial volume index; DBP = diastolic blood pressure; HR = heart rate.
Figure 3. ROC curve analysis of the association between the CHA2DS2-VASc score and exercise intolerance in 
male patients aged <65 (n = 403). ROC = receiver operating characteristic.
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Additionally, the QTc interval was an independent predictor of exercise intolerance in this study. The QTc 
interval has been reported as an electrocardiographic parameter of LV diastolic dysfunction, and a prolonged 
QTc interval is known to be a strong predictor of death due to worsening HF26. Unlike prior studies, our study did 
not show a significant relationship between the resting HR and exercise capacity. However, most data have been 
derived from studies in patients with sinus rhythm, and the prognostic impact of rate control in patients with 
AF is still controversial27,28. Moreover, the type of AF was not associated with the exercise capacity in the present 
study, which was inconsistent with the previously published report showing a higher prevalence of HF in patients 
with persistent or permanent AF than in those with paroxysmal AF29. The detrimental impact of AF on the exer-
cise hemodynamics is well known, but most studies have been conducted in patients with HF or have not focused 
on the type of AF30–32. It is speculated that the presence of AF, rather than the type of AF may be a more important 
factor for determining the exercise capacity in asymptomatic AF patients with a normal LV global systolic func-
tion. We also found that an increased LAVI was associated with exercise intolerance, which is consistent finding 
with the previous reports33. On the other hand, E/E’ was not a significant factor related to exercise intolerance in 
our study. Some studies have been concerned about the limited clinical value of the E/E’ in predicting LV filling 
pressure in patients with normal LVEF, as well as in those with AF34. LAVI seems to be a more reliable echocardi-
ographic parameter for the diagnosis of HFpEF as compared to the E/E’ in patients with AF.
Study limitations. This study had several limitations. First, our study included AF patients who underwent 
TMT as a screening exam. However, TMT was not routinely performed at all hospitals and thus, it was likely that 
patients with relatively more CV risk factors were referred for TMT at tertiary hospitals. Second, we arbitrarily 
defined exercise intolerance as ≤7 METs. Although various MET values have been used to predict adverse prog-
nosis, there has been no widely accepted abnormal value for asymptomatic subjects15. Third, CODE-AF is an 
observational and multicenter registry conducted in patients with AF, so we lacked detailed information on the 
use of diuretics or whether medications were withheld before the exercise stress test. Moreover, the N-terminal 
pro B-type natriuretic peptide, the gold standard biomarker of HF, was not measured in the patients without 
symptoms or signs of HF. Finally, cardiopulmonary exercise testing that provides more comprehensive data on 
the exercise physiology than traditional exercise stress test was not available10.
Conclusion
A higher CHA2DS2-VASc score was independently associated with a lower exercise capacity. Our findings sug-
gested that the CHA2DS2-VASc score may be used to predict exercise intolerance, especially in relatively young 
and middle-aged male patients with asymptomatic AF. Further prospective studies with a long-term follow-up 
might be needed to confirm the prognostic significance of this score for identifying AF patients at a higher risk 
of HF.
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